HIV – Global Clinical Trial Landscape

This report extensively explores the diverse aspects of HIV, including its progression, impact, and global initiatives. It underscores the absence of a cure and emphasizes the effectiveness of antiretroviral therapy (ART) in managing HIV as a chronic condition. Focusing on strategies outlined by WHO, the Global Fund, and UNAIDS to eliminate the HIV epidemic by 2030, the report delves into cutting-edge research on long-acting injectables, HIV vaccines, and gene editing for their potential in enhancing life quality and advancing toward a cure.

In the examination of global HIV epidemiology, variations in prevalence across regions are revealed, with Eastern and Southern Africa experiencing the most significant impact. Socio-economic differences, healthcare access, and cultural practices contribute to varied prevalence rates. Disparities in HIV burdens are detailed, noting substantial impacts in South Africa, India, and the United States until 2022. The report also highlights the persistence of the HIV epidemic among adolescents globally until 2050, as predicted by UNICEF.

Addressing ART's role in preventing mother-to-child transmission and reducing viral replication to undetectable levels, the report acknowledges challenges such as healthcare disruptions and drug resistance. It discusses a diverse array of FDA-approved drugs and recommended initial regimens, emphasizing the importance of personalized treatment strategies.

Providing a comprehensive overview of the global HIV clinical trial landscape since 2018, the report showcases regional leadership, trial phases, and growth rates. It scrutinizes funding distribution by the Global Fund, revealing disparities, with Nigeria leading in total funding allocation.

Ongoing research in HIV treatment, including innovative drug formulations, vaccines, and gene editing, reflects a continuous effort to address unmet needs. The report discusses injectable options, CRISPR-based gene editing, and promising developments by companies like ViiV Healthcare UK Ltd and Gilead Sciences Inc., highlighting a shift towards varied therapy techniques. Interested stakeholders can access the full report below for in-depth insights and analysis.